论文部分内容阅读
作者以17～19月龄要接种常规免疫程序中第4剂脊髓灰质炎疫苗和DTP的425名健康儿童为研究对象,随机分配到含百日咳无细胞菌苗的DTP(DTaP)与MRC-5细胞系生产的脊髓灰质炎灭活疫苗(mIPV)联合接种组和分别接种组;DTaP和Vero细胞
The authors randomized 425 healthy children aged 17-19 months who were challenged with the 4th poliomyelitis vaccine and DTP in routine immunization schedules to DTP (DTaP) and MRC-5 cells containing the B. pertussis acellular vaccine Department of Polio Inactivated Vaccine (mIPV) inoculated group and vaccinated group; DTaP and Vero cells